Roth Capital Downgrades Durata Therapeutics To Neutral

Analysts at Roth Capital downgraded Durata Therapeutics

from Buy to Neutral. The price target for Durata Therapeutics is set to $23. Durata Therapeutics shares have surged 167.64% over the past 52 weeks, while the S&P 500 index has gained 10.58% in the same period. Durata Therapeutics' shares fell 0.04% to close at $23.74 yesterday.